Akari Therapeutics (AKTX) Other Gross PP&E Adjustments (2011 - 2022)
Akari Therapeutics (AKTX) posted quarterly Other Gross PP&E Adjustments of $164938.0 for Q2 2022, little changed year-on-year from $164938.0 in Q2 2021, and little changed on a QoQ basis from $164938.0 in Q2 2021.
Akari Therapeutics (AKTX) Other Gross PP&E Adjustments (2011 - 2022) Analysis & Trends
Akari Therapeutics (AKTX) has reported Other Gross PP&E Adjustments for 9 consecutive years, with $164938.0 the latest figure, recorded in Q2 2022.
- Quarterly Other Gross PP&E Adjustments changed 0.0% year-over-year to $164938.0 in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $164938.0 (changed 0.0% YoY) and the FY2020 annual result came in at $164938.0, changed 0.0% from the prior year.
- Other Gross PP&E Adjustments was little changed at $164938.0 in Q2 2022 per AKTX's latest filing, from $164938.0 in the prior quarter.
- Over the last five years, Other Gross PP&E Adjustments for AKTX reached as high as $164938.0 in Q4 2018 and fell as low as $164938.0 in Q4 2018.
- A 5-year average of $164938.0 and a median of $164938.0 in 2018 frame the typical range for Other Gross PP&E Adjustments.
- The largest YoY upside for Other Gross PP&E Adjustments was 0.0% in 2019 against a maximum downside of 0.0% in 2019.
- Year by year, Other Gross PP&E Adjustments stood at $164938.0 in 2018, then changed by 0.0% to $164938.0 in 2019, then changed by 0.0% to $164938.0 in 2020, then changed by 0.0% to $164938.0 in 2021, then changed by 0.0% to $164938.0 in 2022.
- According to Business Quant data, Other Gross PP&E Adjustments over the past three periods registered $164938.0, $164938.0, and $164938.0 for Q2 2022, Q2 2021, and Q4 2020 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,681.27 Bn | 66,680.98 Bn | - | -3.02 Mn |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.75 Bn | 467.96 Bn | 1.35 Bn | 1.79 Bn |
| 5 | Vertex Pharmaceuticals | 122.14 Bn | 114.89 Bn | 2.59 Bn | -1.69 Bn |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.94 Bn | 50.76 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Revolution Medicines | 37.28 Bn | 37.28 Bn | - | -67.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 164,938.00 |
| Jun 30, 2022 | 164,938.00 |
| Jun 30, 2021 | 164,938.00 |
| Jun 30, 2021 | 164,938.00 |
| Dec 31, 2020 | 164,938.00 |
| Dec 31, 2020 | 164,938.00 |
| Jun 30, 2020 | 164,938.00 |
| Jun 30, 2020 | 164,938.00 |
| Dec 31, 2019 | 164,938.00 |
| Dec 31, 2019 | 164,938.00 |
| Dec 31, 2018 | 164,938.00 |
| Dec 31, 2018 | 164,938.00 |
| Dec 31, 2014 | 67,000.00 |
| Dec 31, 2014 | 67,000.00 |
| Dec 31, 2013 | 10,000.00 |
| Dec 31, 2013 | 10,000.00 |
| Dec 31, 2012 | 13,000.00 |
| Dec 31, 2012 | 13,000.00 |
| Dec 31, 2011 | 9,000.00 |
| Dec 31, 2011 | 9,000.00 |